Pharmacogenomics and antiarrhythmic therapy: An in silico investigation

药物基因组学和抗心律失常治疗：计算机研究

• 批准号: 7407568
• 负责人: COLLEEN E CLANCY
• 金额: $ 33.6万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-15 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7407568
• 关键词: Accounting; Action Potentials; Address; Affect; Affinity; Arrhythmia; Behavior; Binding; Blood; Cardiac; Cell membrane; Cell model; Cells; Charge; Complex; Computer Simulation; Coupled; Dependence; Development; Diagnosis; Diffusion; Drug Delivery Systems; Drug Interactions; Drug Kinetics; Drug Receptors; Drug effect disorder; Effectiveness; Environment; Facility Construction Funding Category; Failure; Genes; Genetic; Genetic Medicine; Genetics and Medicine; Genotype; Goals; Heart Block; Intervention; Investigation; Ion Channel; Ion Channel Gating; Kinetics; Link; Membrane; Modeling; Molecular; Molecular Conformation; Morphology; Movement; Mutation; Numbers; Outcome; Pathway interactions; Pharmaceutical Preparations; Pharmacodynamics; Pharmacogenomics; Pharmacological Treatment; Plasma; Play; Predisposition; Process; Property; Proteins; Protocols documentation; Purpose; Rate; Research; Research Personnel; Role; Simulate; Specificity; System; Testing; Theoretical model; Therapeutic Agents; Time; Tissue Model; Tissues; base; channel blockers; drug mechanism; drug testing; improved; markov model; mutant; novel; prevent; programs; receptor; response; simulation; stem; tool; two-dimensional; virtual; virtual human; voltage

DESCRIPTION (provided by applicant): Pharmacological treatment of cardiac arrhythmia is a long sought and as yet elusive goal. Poor efficacy and outcomes in treating arrhythmia with drugs is due, in part, to failure to accurately predict how drugs with implicitly complex pharmacodynamics affect multi-component interactive cardiac cells and tissues. For example, a representation of drug block of cardiac ion channels as reduced current amplitude is overly simplistic and fails to predict drug effects. Rather, multiple factors including complex drug pharmacokinetics, pH dependence, voltage dependence, conformation-specific block and rate-dependent properties of drugs, as well drug interaction with the multiple mechanisms and triggers of arrhythmia must be considered for development of appropriate pharmacological intervention for arrhythmia management. These issues have been further complicated in the last decade, during which genetic advances have revealed that genes also play a role in determining arrhythmia susceptibility and effectiveness of drug treatment. As a result, it is now clear that, in addition to pharmacodynamics, genotype must be considered as a factor in pharmacological management of arrhythmia. Our goal is to develop novel theoretical approaches through the construction of detailed mathematical pathways of drug block in virtual cardiac cells and tissues to bridge this gap. The long-term purpose of our studies is to develop a framework for accurate prediction of drug interaction with cardiac ion channels, and especially, to predict the emergent effects of mutations and drug block on cellular and tissue level electrical behavior. We will address the following three specific aims: 1: To develop a theoretical framework to simulate pharmacological block of cardiac Na+- channels - A comprehensive model that includes pH dependent partitioning, membrane diffusion, conformation-state specificity of interaction and voltage dependence of Na+ channel block. 2: AIM 2: To utilize the theoretical framework in virtual cardiac cells to examine the effects of Na+ channel block of normal or arrhythmia linked mutant Na+ channels on cell activity. 3: To test, using tissue level simulations, the relationship between pharmacogenomics, drug treatment and arrhythmia. The merit of this proposal lies in the novelty of the approach to test and predict the outcomes of drug interventions intended for diagnosis and treatment of cardiac arrhythmia and represents progress towards a virtual drug testing system.

描述（由申请人提供）：心律失常的药物治疗是一个长期寻求但尚未实现的目标。药物治疗心律失常的疗效和结局不佳，部分原因是无法准确预测具有隐含复杂药效学的药物如何影响多组分相互作用的心脏细胞和组织。例如，将心脏离子通道的药物阻断表示为降低的电流幅度过于简单化，并且无法预测药物作用。相反，开发适当的药物干预治疗心律失常必须考虑多种因素，包括复杂的药物药代动力学、pH依赖性、电压依赖性、药物的构象特异性阻断和速率依赖性，以及药物与心律失常的多种机制和触发因素的相互作用。在过去的十年中，这些问题变得更加复杂，在此期间，遗传学的进展表明，基因也在决定心律失常的易感性和药物治疗的有效性方面发挥作用。因此，现在很清楚，除了药效学，基因型必须被视为心律失常的药理学管理的一个因素。我们的目标是通过构建虚拟心脏细胞和组织中药物阻断的详细数学途径来开发新的理论方法，以弥合这一差距。我们研究的长期目的是建立一个准确预测药物与心脏离子通道相互作用的框架，特别是预测突变和药物阻断对细胞和组织水平电行为的紧急影响。我们将解决以下三个具体目标：1：建立一个理论框架，以模拟心脏Na+通道的药理学阻断-一个全面的模型，包括pH依赖性分区，膜扩散，构象-状态特异性的相互作用和电压依赖性的Na+通道阻滞。第二章：目标2：利用虚拟心肌细胞的理论框架，研究正常或心律失常相关突变型Na+通道的Na+通道阻断对细胞活性的影响。3：使用组织水平模拟测试药物基因组学、药物治疗和心律失常之间的关系。该提案的优点在于测试和预测用于诊断和治疗心律失常的药物干预的结果的方法的新奇，并且代表了朝向虚拟药物测试系统的进展。